$INSP
Inspire Medical Systems, Inc.

2021 Q2 Form 10-Q Financial Statement

#000160955021000038 Filed on August 03, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2
Revenue $52.96M $12.18M
YoY Change 334.7% -32.44%
Cost Of Revenue $7.518M $1.954M
YoY Change 284.75% -36.85%
Gross Profit $45.44M $10.23M
YoY Change 344.24% -31.52%
Gross Profit Margin 85.8% 83.96%
Selling, General & Admin $48.70M $26.98M
YoY Change 80.49% 33.1%
% of Gross Profit 107.17% 263.76%
Research & Development $9.288M $6.062M
YoY Change 53.22% 113.0%
% of Gross Profit 20.44% 59.26%
Depreciation & Amortization $308.0K $190.0K
YoY Change 62.11% 72.73%
% of Gross Profit 0.68% 1.86%
Operating Expenses $57.99M $33.04M
YoY Change 75.48% 42.96%
Operating Profit -$12.54M -$22.81M
YoY Change -45.02% 179.04%
Interest Expense $530.0K $526.0K
YoY Change 0.76% 0.57%
% of Operating Profit
Other Income/Expense, Net -$518.0K -$275.0K
YoY Change 88.36% -152.28%
Pretax Income -$13.06M -$23.09M
YoY Change -43.43% 201.82%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$13.09M -$23.09M
YoY Change -43.31% 201.82%
Net Earnings / Revenue -24.71% -189.52%
Basic Earnings Per Share -$0.48 -$0.88
Diluted Earnings Per Share -$0.48 -$0.88
COMMON SHARES
Basic Shares Outstanding 27.23M shares 26.29M shares
Diluted Shares Outstanding 27.23M shares 26.29M shares

Balance Sheet

Concept 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $207.8M $242.6M
YoY Change -14.33% 52.96%
Cash & Equivalents $176.5M $211.2M
Short-Term Investments $31.30M $31.30M
Other Short-Term Assets $3.448M $4.300M
YoY Change -19.81% -23.21%
Inventory $13.30M $9.966M
Prepaid Expenses $3.448M $4.348M
Receivables $24.91M $10.24M
Other Receivables $0.00 $0.00
Total Short-Term Assets $249.5M $267.1M
YoY Change -6.59% 50.7%
LONG-TERM ASSETS
Property, Plant & Equipment $7.066M $3.307M
YoY Change 113.67% 81.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $9.979M $0.00
YoY Change -100.0%
Other Assets $204.0K $500.0K
YoY Change -59.2% 25.0%
Total Long-Term Assets $22.71M $4.200M
YoY Change 440.81% -49.54%
TOTAL ASSETS
Total Short-Term Assets $249.5M $267.1M
Total Long-Term Assets $22.71M $4.200M
Total Assets $272.2M $271.3M
YoY Change 0.33% 46.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.681M $5.100M
YoY Change 70.22% 88.89%
Accrued Expenses $12.61M $7.939M
YoY Change 58.79% 32.76%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $3.063M
YoY Change
Total Short-Term Liabilities $24.35M $13.04M
YoY Change 86.7% 50.58%
LONG-TERM LIABILITIES
Long-Term Debt $21.80M $24.60M
YoY Change -11.38% 0.82%
Other Long-Term Liabilities $111.0K $40.00K
YoY Change 177.5%
Total Long-Term Liabilities $111.0K $40.00K
YoY Change 177.5% -99.84%
TOTAL LIABILITIES
Total Short-Term Liabilities $24.35M $13.04M
Total Long-Term Liabilities $111.0K $40.00K
Total Liabilities $52.29M $37.71M
YoY Change 38.66% 14.02%
SHAREHOLDERS EQUITY
Retained Earnings -$266.7M -$219.5M
YoY Change 21.49% 34.79%
Common Stock $27.00K $27.00K
YoY Change 0.0% 12.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $219.9M $233.6M
YoY Change
Total Liabilities & Shareholders Equity $272.2M $271.3M
YoY Change 0.33% 46.21%

Cashflow Statement

Concept 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$13.09M -$23.09M
YoY Change -43.31% 201.82%
Depreciation, Depletion And Amortization $308.0K $190.0K
YoY Change 62.11% 72.73%
Cash From Operating Activities -$10.12M -$25.25M
YoY Change -59.94% 95.89%
INVESTING ACTIVITIES
Capital Expenditures -$1.664M -$380.0K
YoY Change 337.89% -60.0%
Acquisitions
YoY Change
Other Investing Activities $2.507M $34.30M
YoY Change -92.69% -190.12%
Cash From Investing Activities $843.0K $33.92M
YoY Change -97.51% -186.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.479M 126.4M
YoY Change -97.25% 10015.2%
NET CHANGE
Cash From Operating Activities -10.12M -25.25M
Cash From Investing Activities 843.0K 33.92M
Cash From Financing Activities 3.479M 126.4M
Net Change In Cash -5.793M 135.1M
YoY Change -104.29% -366.65%
FREE CASH FLOW
Cash From Operating Activities -$10.12M -$25.25M
Capital Expenditures -$1.664M -$380.0K
Free Cash Flow -$8.451M -$24.87M
YoY Change -66.02% 108.29%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001609550
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2020Q1 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38468
dei Entity Registrant Name
EntityRegistrantName
Inspire Medical Systems, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-1377674
dei Entity Address Address Line1
EntityAddressAddressLine1
5500 Wayzata Blvd.
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1600
dei Entity Address City Or Town
EntityAddressCityOrTown
Golden Valley
dei Entity Address State Or Province
EntityAddressStateOrProvince
MN
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
55416
dei City Area Code
CityAreaCode
844
dei Local Phone Number
LocalPhoneNumber
672-4357
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
INSP
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27271598 shares
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
176541000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
190518000 USD
CY2021Q2 us-gaap Short Term Investments
ShortTermInvestments
31295000 USD
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
43844000 USD
CY2021Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
32000 USD
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
42000 USD
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
24914000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
25063000 USD
CY2021Q2 us-gaap Inventory Net
InventoryNet
13296000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
8479000 USD
CY2020Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
7209000 USD
CY2021Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3448000 USD
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1965000 USD
CY2021Q2 us-gaap Assets Current
AssetsCurrent
249494000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
269869000 USD
CY2021Q2 us-gaap Long Term Investments
LongTermInvestments
9979000 USD
CY2020Q4 us-gaap Long Term Investments
LongTermInvestments
0 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7066000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5311000 USD
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5465000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5805000 USD
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
204000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
204000 USD
CY2021Q2 us-gaap Assets
Assets
272208000 USD
CY2020Q4 us-gaap Assets
Assets
281189000 USD
CY2021Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
8681000 USD
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
111000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
85000 USD
CY2021Q2 us-gaap Liabilities
Liabilities
52294000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
51442000 USD
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12606000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13516000 USD
CY2021Q2 us-gaap Notes Payable Current
NotesPayableCurrent
3063000 USD
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0 USD
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
24350000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20725000 USD
CY2021Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
21801000 USD
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
24746000 USD
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6032000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5886000 USD
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27264071 shares
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27264071 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27069276 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27069276 shares
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
27000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
27000 USD
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
486550000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
467038000 USD
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-12000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
29000 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-266651000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-237347000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
219914000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
229747000 USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
272208000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
281189000 USD
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
52959000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12183000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
93311000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33530000 USD
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7518000 USD
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1954000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13499000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5251000 USD
CY2021Q2 us-gaap Gross Profit
GrossProfit
45441000 USD
CY2020Q2 us-gaap Gross Profit
GrossProfit
10229000 USD
us-gaap Gross Profit
GrossProfit
79812000 USD
us-gaap Gross Profit
GrossProfit
28279000 USD
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9288000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6062000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17442000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11500000 USD
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
48697000 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26981000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
90603000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
56033000 USD
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
57985000 USD
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
33043000 USD
us-gaap Operating Expenses
OperatingExpenses
108045000 USD
us-gaap Operating Expenses
OperatingExpenses
67533000 USD
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12544000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-22814000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-28233000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-39254000 USD
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
31000 USD
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
248000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
88000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
890000 USD
CY2021Q2 us-gaap Interest Expense
InterestExpense
530000 USD
CY2020Q2 us-gaap Interest Expense
InterestExpense
526000 USD
us-gaap Interest Expense
InterestExpense
1053000 USD
us-gaap Interest Expense
InterestExpense
1051000 USD
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-19000 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-57000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
81000 USD
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-518000 USD
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-275000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1022000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-80000 USD
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13062000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23089000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29255000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-39334000 USD
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
26000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
49000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-13088000 USD
CY2020Q2 us-gaap Profit Loss
ProfitLoss
-23089000 USD
us-gaap Profit Loss
ProfitLoss
-29304000 USD
us-gaap Profit Loss
ProfitLoss
-39334000 USD
CY2021Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-21000 USD
CY2020Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-141000 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-41000 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
52000 USD
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13109000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23230000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29345000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39282000 USD
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.88
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.56
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27230044 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27230044 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26289272 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26289272 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27187438 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27187438 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25227574 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25227574 shares
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
229747000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3550000 USD
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
73000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
5997000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-20000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-16216000 USD
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
223131000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1719000 USD
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
72000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1760000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
6341000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-21000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-13088000 USD
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
219914000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
139835000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
787000 USD
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
72000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2749000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
193000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-16245000 USD
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
127403000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
732000 USD
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
73000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1059000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2903000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-141000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-23089000 USD
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
233594000 USD
us-gaap Profit Loss
ProfitLoss
-29304000 USD
us-gaap Profit Loss
ProfitLoss
-39334000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
538000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
375000 USD
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
23000 USD
us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
88000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
117000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
110000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
340000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
491000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
12338000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
5652000 USD
insp Sharebased Compensation Noncash Services
SharebasedCompensationNoncashServices
145000 USD
insp Sharebased Compensation Noncash Services
SharebasedCompensationNoncashServices
145000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
11000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
98000 USD
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-126000 USD
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-2905000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4816000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4131000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1483000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2233000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2189000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
639000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-717000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4459000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20515000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40026000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2984000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
636000 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
9993000 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
14907000 USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
12500000 USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
116703000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-477000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
101160000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5269000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1519000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
124654000 USD
insp Proceeds From Issuance Of Common Stock From Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockFromEmployeeStockPurchasePlan
1760000 USD
insp Proceeds From Issuance Of Common Stock From Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockFromEmployeeStockPurchasePlan
1059000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7029000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
127232000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-14000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13977000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
188377000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
190518000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22860000 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
176541000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
211237000 USD
us-gaap Interest Paid Net
InterestPaidNet
941000 USD
us-gaap Interest Paid Net
InterestPaidNet
947000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
691000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0 USD
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
100000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
100000 USD
CY2020 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
100000 USD
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0 USD
CY2021Q2 insp Investments Allowance For Credit Loss
InvestmentsAllowanceForCreditLoss
0 USD
CY2020Q4 insp Investments Allowance For Credit Loss
InvestmentsAllowanceForCreditLoss
0 USD
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject us to concentrations of credit risk, consist principally of cash equivalents, investments, and accounts receivable. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment policy limits investments to certain types of debt securities issued by the U.S. government and its agencies, corporations with investment-grade credit ratings, or commercial paper and money market funds issued by the highest quality financial and non-financial companies. We place restrictions on maturities and concentration by type and issuer. We are exposed to credit risk in the event of a default by the issuers of these securities to the extent recorded on the balance sheets. However, as of June 30, 2021 and December 31, 2020, we limited our credit risk associated with cash equivalents by placing investments with banks we believe are highly creditworthy.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the credit risk in our accounts receivable is mitigated by our credit evaluation process, relatively short collection terms, and dispersion of our customer base. We generally do not require collateral, and losses on accounts receivable have historically been within management's expectations.</span></div>
CY2021Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1521000 USD
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
892000 USD
CY2021Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
11775000 USD
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
7587000 USD
CY2021Q2 us-gaap Inventory Net
InventoryNet
13296000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
8479000 USD
CY2021Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
200000 USD
CY2020Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
100000 USD
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9438000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7156000 USD
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2372000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1845000 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7066000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5311000 USD
CY2021Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000 USD
CY2020Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
500000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
400000 USD
CY2021Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
10516000 USD
CY2020Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
11965000 USD
CY2021Q2 us-gaap Interest Payable Current
InterestPayableCurrent
155000 USD
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
160000 USD
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1935000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1391000 USD
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12606000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13516000 USD
CY2021Q2 insp Operating Leases Future Minimum Payments Net Present Value
OperatingLeasesFutureMinimumPaymentsNetPresentValue
7400000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q2 us-gaap Advertising Expense
AdvertisingExpense
11500000 USD
CY2020Q2 us-gaap Advertising Expense
AdvertisingExpense
5000000.0 USD
us-gaap Advertising Expense
AdvertisingExpense
20600000 USD
us-gaap Advertising Expense
AdvertisingExpense
11400000 USD
CY2021Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0 USD
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5465000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5805000 USD
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6032000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5886000 USD
insp Operating Lease Remaining Lease Term
OperatingLeaseRemainingLeaseTerm
P6Y10M24D
CY2021Q2 insp Operating Lease Remaining Lease Discount Rate Percent
OperatingLeaseRemainingLeaseDiscountRatePercent
0.052
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
100000 USD
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
200000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
100000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
500000 USD
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0 USD
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
9188000 USD
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
12250000 USD
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
3062000 USD
CY2021Q2 us-gaap Long Term Debt
LongTermDebt
24500000 USD
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6341000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2903000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12338000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5652000 USD
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6341000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2903000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12338000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5652000 USD
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2857564 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
66.09
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
351626000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
145484 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
205.65
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
182739 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
28.91
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
32277000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
74206 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
110.14
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2746103 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
74.77
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
327813000 USD
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1323529 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
27.17
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y3M18D
insp Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable
219823000 USD
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
73100000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2021Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
100000 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
100000 USD
CY2021Q2 us-gaap Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit
SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
0 USD
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
52959000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12183000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
93311000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33530000 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2748378 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2649221 shares

Files In Submission

Name View Source Status
0001609550-21-000038-index-headers.html Edgar Link pending
0001609550-21-000038-index.html Edgar Link pending
0001609550-21-000038.txt Edgar Link pending
0001609550-21-000038-xbrl.zip Edgar Link pending
a2021-q2ex10x1.htm Edgar Link pending
a2021-q2ex31x1.htm Edgar Link pending
a2021-q2ex31x2.htm Edgar Link pending
a2021-q2ex32x1.htm Edgar Link pending
a2021-q2ex32x2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
insp-20210630.htm Edgar Link pending
insp-20210630.xsd Edgar Link pending
insp-20210630_cal.xml Edgar Link unprocessable
insp-20210630_def.xml Edgar Link unprocessable
insp-20210630_g1.jpg Edgar Link pending
insp-20210630_htm.xml Edgar Link completed
insp-20210630_lab.xml Edgar Link unprocessable
insp-20210630_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending